<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02537977</url>
  </required_header>
  <id_info>
    <org_study_id>TJ1537</org_study_id>
    <nct_id>NCT02537977</nct_id>
  </id_info>
  <brief_title>CD19-directed CAR T Cells Therapy in Relapsed/Refractory B Cell Malignancy</brief_title>
  <official_title>CD19-directed Chimeric Antigen Receptor T Cells Therapy in Relapsed/Refractory B Cell Malignancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Tongji Hospital, Tongji University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Tongji Hospital, Tongji University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Relapsed/refractory leukemia and lymphoma lack effective treatment. The cancer immunotherapy&#xD;
      with chimeric antigen receptor (CAR) T cells provides a potent new approach for them. In this&#xD;
      clinical trial, the investigators aim to assess the safety and efficacy of administering T&#xD;
      cell expressing an anti-CD19 CARs to patients with chemotherapy resistant or refractory CD19&#xD;
      positive B cell malignancy including leukemia and lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tongji Hospital of Tongji University has developed an investigational approach for treating&#xD;
      patients with CD19 positive B cell malignancy that involves taking white blood cells from the&#xD;
      patient, growing them in the laboratory in large numbers, genetically modifying these&#xD;
      specific cells with lentivirus to attack CD19 positive cells, and then giving the cells back&#xD;
      to the patients.The main purpose of the study is to assess the safety and efficacy of the&#xD;
      treatment with anti-CD19 CAR-T cells in the patients with chemotherapy resistant or&#xD;
      refractory CD19 positive B cell malignancy including leukemia and lymphoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of study related adverse events</measure>
    <time_frame>2 years</time_frame>
    <description>defined as &gt;= Grade 3 signs/symptoms, laboratory toxicities, and clinical events) that are possibly，likely，or definitely related to the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rates to CAR-T cells</measure>
    <time_frame>2 years</time_frame>
    <description>Describe the response rates of patients treated with CAR-T cells, including complete remission, partial remission,stable disease and progression disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival(PFS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of remission(DOR)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival(OS) of patients treated with CAR-T cells</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>CAR-T cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous 2nd generation CD19-directed CAR-T cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CD19-directed CAR-T cells</intervention_name>
    <description>CD19-directed CAR-T cell infusion will be given by vein</description>
    <arm_group_label>CAR-T cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with CD19+ leukemia or lymphoma, meeting the following criteria:&#xD;
&#xD;
               -  At least 2 prior combination chemotherapy regimens (not including single agent&#xD;
                  monoclonal antibody (Rituximab) therapy)&#xD;
&#xD;
               -  Less than 1 year between last chemotherapy and progression&#xD;
&#xD;
               -  Not eligible or appropriate for allo-HSCT&#xD;
&#xD;
          -  To be aged 6 to 85 years&#xD;
&#xD;
          -  Estimated survival of ≥ 6 months, but ≤ 2 years&#xD;
&#xD;
          -  ECOG score ≤2&#xD;
&#xD;
          -  Relapse after auto-HSCT&#xD;
&#xD;
          -  Women of childbearing potential must have a urine pregnancy test taken and proven&#xD;
             negative prior to the treatment. All patients agree to use reliable methods of&#xD;
             contraception during the trial period and until follow-up for the last time&#xD;
&#xD;
          -  Voluntary participation in the clinical trials and sign the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of epilepsy or other CNS disease&#xD;
&#xD;
          -  Patients have GVHD, which needs treatment with immunosuppressive agents&#xD;
&#xD;
          -  Patients with prolonged QT interval or severe heart disease&#xD;
&#xD;
          -  Patients in pregnancy or breast-feeding period&#xD;
&#xD;
          -  Uncontrolled active infection&#xD;
&#xD;
          -  Active hepatitis B or hepatitis C infection&#xD;
&#xD;
          -  Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not&#xD;
             exclusionary&#xD;
&#xD;
          -  Previously treatment with any gene therapy products&#xD;
&#xD;
          -  Feasibility assessment during screening demonstrates &lt;20% transduction of target&#xD;
             lymphocytes, or insufficient expansion (&lt;5-fold) in response to CD3/CD28 costimulation&#xD;
&#xD;
          -  ALT /AST&gt;3 x normal value; Creatinine&gt; 2.5 mg/dl; Bilirubin &gt;2.0 mg/dl&#xD;
&#xD;
          -  Any uncontrolled medical disorders that the researchers consider are not eligible to&#xD;
             participate the clinical trial&#xD;
&#xD;
          -  HIV infection&#xD;
&#xD;
          -  Any situation that would increase dangerousness of subjects or disturb the outcome of&#xD;
             the clinical study according to the researcher's evaluation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aibin Liang, MD,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Tongji Hospital, Tongji University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aibin Liang, MD,Ph.D.</last_name>
    <phone>0086-021-66111019</phone>
    <email>lab7182@tongji.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ping Li, MD,Ph.D.</last_name>
    <phone>0086-021-66111015</phone>
    <email>lilyforever76@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Tongji Hospital, Tongji University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <zip>200065</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aibin Liang, MD,Ph.D.</last_name>
      <phone>0086-021-66111019</phone>
      <email>lab7182@tongji.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>August 26, 2015</study_first_submitted>
  <study_first_submitted_qc>August 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2015</study_first_posted>
  <last_update_submitted>November 29, 2018</last_update_submitted>
  <last_update_submitted_qc>November 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Tongji Hospital, Tongji University School of Medicine</investigator_affiliation>
    <investigator_full_name>Aibin Liang，MD，Ph.D.</investigator_full_name>
    <investigator_title>Director，Department of Hematology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

